

DR. ERIN I WALSH (Orcid ID : 0000-0001-8941-0046)

PROF. PERMINDER S. SACHDEV (Orcid ID : 0000-0002-9595-3220)

Article type : Original Article

The impact of type 2 diabetes and body mass index on cerebral structure is modulated by brain reserve

Erin I. Walsh, PhD^{1*}, Marnie Shaw, PhD², Perminder Sachdev MD, PhD, FRANZCP³,
Kaarin J. Anstey PhD^{1,4}, Nicolas Cherbuin PhD¹

1. Centre for Research on Ageing, Health and Wellbeing, Australian National University

2. College of Engineering and Computer Science, Australian National University

3. School of Psychiatry, University of New South Wales, Sydney, Australia

4. Neuroscience Research Australia (NeuRA), University of New South Wales

***Corresponding author:** Dr. Erin I. Walsh

54 Mills Road, ANU, Acton, ACT, 2601.

61261258291

erin.walsh@anu.edu.au

Keywords: MRI; Diabetes; Adult; Epidemiology

Running title: BMI, glucose, diabetes and brain

Conflict of interest: None.

Abstract

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ene.13780](https://doi.org/10.1111/ene.13780)

This article is protected by copyright. All rights reserved

Background: BMI, hyperglycaemia and Type 2 Diabetes (T2D), and their interactive effects are associated with brain volume atrophy in ageing. It remains to be established if these risk factors are particularly concerning in individuals with high or low brain volumes.

Methods: Demographics, venous blood and MRI data were collected for 494 healthy community-living adults aged 53-78 ($M=65$), as part of the Personality and Total Health Through Life study. Associations between Body Mass Index (BMI), blood glucose, diabetes status and brain volume (whole brain, grey matter, white matter, and sub-cortical structures) was investigated using quantile regression.

Results: Quantile regression revealed particular vulnerability to BMI x glucose interactions in lower volumes, and significant main effects for T2D particularly in higher volumes.

Diabetes was most strongly associated with brain volumes. The association between BMI, blood glucose and diabetes is not consistent across the full range of brain volumes.

Conclusion: Explicit investigation of the upper and lower boundaries of brain volume distributions is valuable. We found evidence of protective reserve from higher brain volumes, and that a combination of high BMI and higher blood glucose was particularly concerning for individuals with lower brain volumes.

Introduction

Brain tissue loss occurs throughout the adult lifespan but increases progressively with age. By age 80, typical shrinkage is estimated to be around 10% of original total brain volume and is an important contributor to loss of cognitive function[1]. Better understanding of how modifiable risk factors contribute to neurodegeneration is critical to the development of strategies aimed at optimising healthy brain ageing, and at decreasing the risk of dementia. There is substantial evidence indicating that type 2 diabetes mellitus (T2D) and overweight/obesity (often measured as BMI) are both associated with accelerated brain atrophy, neurodegeneration, and increased risk of cognitive decline[2]. However, although they co-occur and share a number of pathological features, it is not clear whether one or the other contributes more to neurodegeneration. Moreover, whether their effect is uniform across cerebral structures and individuals is not well understood[3].

T2D is associated with lower total brain volume and accelerated brain atrophy throughout life [2, 4]. This amounts to approximately 1.5% lower brain volume in adults with T2D, equivalent to three years of age-associated atrophy[5]. There is growing evidence that high blood glucose levels in the non-diabetic range are also implicated in brain tissue loss well before clinical T2D sets in [6].

High BMI is also associated with lower total brain volume and accelerated brain atrophy over time, amounting to approximately 6% lower brain volume in adults with obesity, who experience 20% more atrophy per year than individuals of normal weight[2]. Because obesity and T2D are highly comorbid, overlap in their pathophysiology, and share several pathways to affect cerebral health, it is unresolved which contributes most to neurodegenerative processes, and the extent to which they interact

A promising new approach is to focus on blood glucose levels, both because blood glucose in the normal range can impact cerebral health. To our knowledge the only study to have examined in detail the overlap in effects between high BMI and T2D while also considering blood glucose, suggested that T2D effects on white matter may be secondary to co-morbid obesity. However, these conclusions are limited by a small sample and a unique focus on white matter[4]. It is unclear whether grey matter might be differentially affected. For example, brain regions with high insulin receptor density, such as the hippocampus[7], may be particularly vulnerable to hyperinsulinemia from both T2D and obesity. Investigation of structures with low insulin receptor density that are also vulnerable to hyperglycemia, such as the thalamus[8], may therefore help to distinguish T2D from obesity effects.

A growing body of evidence suggests that those with smaller intracranial, total brain, and subcortical volumes may be at increased risk of subsequent brain atrophy and pathological cognitive decline[2, 9]. Lower volumes appear to be associated with increased vulnerability to physical and psychological risk factors and consequent neurodegeneration[10]. This can be framed as limited reserve for coping with additional impact of high blood glucose, T2D and high BMI. Conversely, larger brain volumes may constitute protective reserve[11]. The aim of this study was therefore to investigate the association between BMI, blood glucose, T2D, and brain volume in a large sample of community-living middle-and older-aged individuals.

Methods

Study population

This cross-sectional study focusses on a the recent wave (4) of the Personality and Total Health (PATH) Through Life study is a large longitudinal study investigating ageing, health, cognition and other individual characteristics across the lifespan described in detail elsewhere[12]. Briefly, a large cohort of healthy community-living adults provided self-

report, blood, and MRI data at four year intervals over a twelve year period. The current study focusses on follow-up data for cohorts aged 40-45 ($n=2530$) and 60-64 years at baseline ($n=2551$). Participants were excluded on the basis of unavailable MRI data at the wave of interest (wave 4), and history of neurological disorders (epilepsy, Parkinson's disease, stroke, or dementia), at any time during the PATH study resulting in a final sample of 494 (40s $n=266$, 60s $n=228$; see supplementary materials). Included/excluded differed only in years of education (included $M=14.13$, excluded $M=14.41$; $t(617)=2.239$, $p<0.02$). Participants provided written, informed consent. This study was approved by the human research ethics committees of the Australian National University and the University of New South Wales.

Measures

Body mass index (BMI) was computed based on self-reports of weight and height with the formula weight (kg)/height (m^2). Venous blood was collected following an overnight fast, and plasma glucose was measured on a Beckman LX20 Analyzer by an oxygen rate method. Diabetic status was defined by non-overlapping categories of T2D (self-reported, or two or more fasting blood glucose measures during the study >7 mmol/L), impaired fasting glucose (IFG; not T2D and two or more blood glucose measures during the study ≥ 5.6 mmol/L), or NFG (not T2D or IFG, two or more blood glucose measures during the study <5.6), following American Diabetes Association guidelines. Years of education, smoking (ever vs never smoked) and neurological exclusion criterion (listed previously) were obtained by self-report. Hypertension was assessed by self-reported use of antihypertensive medication, or two blood pressure measures taken three minutes apart while participants were seated (systolic > 140 , diastolic > 90). Physical activity, expressed as Metabolic Equivalents (METs), was calculated from self-reported hours physical activity(mild PA $\times 3$)+(moderate PA $\times 6$)+(vigorous PA $\times 9$), following the ratio in Ainsworth et al[13]. Acquisition parameters for MRI scans are described in detail elsewhere[14] and in the supplementary materials. Briefly, scans were three-dimensional structural fast-field echo sequence T1-weighted, analyzed using the longitudinal pipeline of Freesurfer v5.3 on a Linux workstation [15]. This study focusses on wave 4 total brain, grey matter, thalamus (left+right), white matter, and corpus callosum volume.

Statistical analyses

Analyses were carried out in R version 3.2.0. Main effects models for each brain volume (total, grey matter, thalamus, white matter, and corpus callosum) were fit with BMI, glucose, and diabetes status (NFG/IFG/T2D) as predictors. Separate models were fit for the BMI x glucose and BMI x diabetes status interactions, to allow separate interpretation of main effects and interactions. All models controlled for intracranial volume, sex, age, cohort (40s/60s), years of education, hypertension (yes/no), smoking status (ever/never) and physical activity (METs). Linear regression and corresponding quantile models were fit with `quantreg` v5.21.

Comparison of quantile sub-models against the linear results provides insight into whether predictors have a constant association across the whole range of brain volumes, taking into account heterogeneity of variance in ways that alternative approaches that may deal with such nonlinearity, such as spline models, cannot. Wald tests of equality of slopes indicated whether models (joint test) and/or slopes (non-joint test) for each sub-model within the quantile regression differed from one another. Linear and quantile models explain variance in distinct ways, thus we used the Akaike Information Criterion (AIC) and -2 Log Likelihood (-2LL) via χ^2 ratio test.

Four groups were specified with cut points of tau 0.25, 0.5, and 0.75 to allow comparison of the centre, upper 25th percentile, and lower 25th percentile of the distribution. Three cut points were chosen to maintain sufficient power at each tau. Alpha was adjusted for multiple comparisons at <0.05, or <0.01 (conservatively, linear model and four quantile slopes = $0.05/4 = 0.01$).

Results

Just over half (n=251, 50.81%) of participants were male. Around 20% (n=95) had IFG, and 10% (n=46) had T2D. Further participant characteristics can be seen in table 1, and quartile cut points can be seen in table 2. Wald tests indicated that quantile sub-model fit significantly differed for main effects and interactions in grey matter (QRAD(24,1224)=1.70, $p=0.02$ and QRAD(26,1222)=1.76, $p=0.01$ respectively; see supplementary table 1). -2LL and AIC fit indices similarly indicated a trend for superior fit in quartile models regarding grey matter volume (supplementary table 2). Accordingly, main effects from linear model coefficients

will be reported to provide context for whole-sample trends (for comparison with other literature which takes a linear approach), but the better fitting quartile models will form the basis of interpretation and conclusions.

Main effect associations with blood glucose and diabetes

Blood glucose was significantly associated with grey matter ($\tau=0.50$, $b=3.98$ 95%CI[-6.23, -1.74]) the thalamus (significance at $\tau=0.25$, $b=-0.09$ 95%CI[-0.18, -0.01]) volume (Figure 1). In fully adjusted models, participants with T2D had 28.28ml [95%CI -47.21, -9.36] lower total brain volume, 9.45ml [95%CI -21.69, 2.77] lower grey matter volume, 0.44ml [95%CI -0.91, 0.04] lower thalamus volume, -16.23ml [95%CI -29.23, -3.23] lower white matter volume, and -0.17ml [95%CI -0.36, 0.01] lower corpus callosum volume. The association between T2D and smaller brain volumes was most pronounced in the 75th percentile (Figure 1), indicating that the significant impact of T2D on brain volume is driven but the upper end of the distribution.

Main effect associations with BMI

The main effect for BMI was not significantly associated with any brain volume, though there was a trend for individuals in the 25th percentile to have a positive association with brain volumes, while those in the 50th and 75th percentiles were closer to neutral or negative associations (figure 1).

Interactions between BMI, blood glucose levels and T2D

BMI and blood glucose interacted to predict volumes. Significance was not uniform across quartiles. In the 25th percentile, the BMI x glucose interaction was associated with lower volume, specifically 0.61ml [95%CI -1.22, -0.01] lower total brain and 0.01ml [95%CI -0.02, -0.01] lower thalamus matter volume, and borderline significance for grey matter volume. This indicates that the combination of high BMI and high blood glucose is a risk factor particular to individuals with low brain volumes at baseline. In the 75th percentile, BMI and diabetes status significantly interacted. Each additional unit of BMI was associated with 3ml [95%CI 1.04, 5.02] greater total brain volume in individuals with IFG, adding to the main effect trend for higher total brain volume associated with IFG. In white matter, having T2D (rather than NFG) mitigated the main effect negative association between BMI and brain volume by 2ml [95%CI 0.06, 4.04] per unit BMI (figure 1).

Sensitivity analyses

Additional models (see supplementary materials) were run with outliers removed, without covariates, without or adjustment for diabetes, with additional adjustment for physical activity, and with an additional adjustment for cholesterol. The pattern of associations were broadly consistent. Analyses were repeated with quantile splits based on intracranial volume rather than individual brain regions to partially address whether these effects are more likely due to smaller pre-morbid head size or neurodegeneration. While broadly similar, some divergence indicated current results are likely explained by a mix of initial brain volume and prior pathological shrinkage.

Discussion

This study's main findings were that BMI and glucose interact in their associations with brain volumes, and that these associations depend on the brain volumes (large or small) of those investigated. A quantile approach, which allows investigation of the lower and upper distribution of brain volumes, provided better model fit and more nuanced information than a linear model. This approach indicated a more complex pattern of associations that differed depending on whether participants had a particularly high or low (intracranial volume adjusted) total brain, grey matter, thalamus, white matter, or corpus callosum volume.

T2D was associated with lower brain volumes[2, 4], and contributed more to neurodegeneration than BMI in both white and grey matter. BMI was not directly associated with neurodegeneration, even in the corpus callosum, contrary to previous studies[16].

However, significant interactions with glucose and T2D status indicates that BMI a combination of high BMI and higher blood glucose was particularly concerning for individuals with lower brain volumes, seen in total brain volumes and specifically in the thalamus. This may be indicative of an ongoing atrophy process putatively linked to high glucose and BMI within these individuals, or alternatively, diminished reserve in lower volumes leading to increased vulnerability. Lack of significance in sensitivity analyses using intracranial volume as a proxy for pre-morbid brain size suggest that these effects are more likely due to neurodegenerative processes than initially smaller brain size. This possibility would be most convincingly clarified via comparison of monozygotic twins with differential glycaemic histories.

Results supported the presence of protective reserve associated with larger brain volumes[11]. In individuals with larger brain volumes only, a combination of IFG and high BMI was positively associated with total brain volume in individuals with IFG, though the

magnitude of the effect was small (<1% total brain volume per unit BMI). This may be indicative of protective compensatory pre-diabetic metabolic changes to blood glucose metabolism in higher body weights, or conversely, pathological volume increase associated with inflammation from chronically high blood glucose levels. If the latter is the case, there was little indication that this persists in T2D. While T2D was universally significantly associated with lower volumes in the largest volumes, the association was (barring the thalamus) consistently lower in magnitude and non-significant in those with the lowest volumes. This may indicate previous atrophy processes leave limited room for additional neurodegenerative effects. Together, this suggests simultaneous protective or compensatory processes preserving brain volume in some individuals, and exhaustion of degenerative processes, but the nature of these processes remain unclear.

The thalamus has a comparatively lower insulin receptor density than other well-studied grey matter structures such as the hippocampus[7, 8], and so may be more clearly associated with hyperglycemia (rather than hyperinsulinemia). The relationship between thalamus volume and T2D was of similar magnitude as in other insulin-receptor rich structures reported elsewhere (here, thalamus volume was 5% lower in T2D; elsewhere hippocampus volume was ~4.4% lower in T2D[17]), demonstrating that the thalamus is vulnerable to of type 2 as well as type 1 diabetes[8]. Interestingly, the association between glucose and thalamus volume was significant only in the lowest percentile, while it was associated both the lowest and highest percentile in T2D. Together with significant interactions between BMI and glucose in this percentile, this suggests that the thalamus may be a useful structure for isolating the potential impact of hyperglycemia absent hyperinsulinemia on grey matter, but only in individuals with low reserve. Similarly, this indicates some differentiation in the association between the thalamus and high blood glucose per se versus T2D. This supports our previous findings that T2D and high glucose levels are not necessarily synonymous due to glycaemic management, and so can have differing impacts on the brain[18].

This study has a number of strengths, and limitations. Though cross-sectional, cohort effects in the current study were limited by the use of two narrow age bands and controlling for both cohort and time in all models. Further, while the sample was combined in the interests of statistical power and analytical clarity, it is possible that different mechanisms underlie BMI in different cohorts (e.g. skeletal muscle loss in the 60s). Although brain volumes and rates of overweight and T2D were on par with global estimates[19], this limited variability at the lower ranges of BMI, possibly obscuring the influence of low BMI, and was

reflected in a small proportion of the youngest cohort having T2D, though the number of individuals with IFG or T2D were sufficient for analysis when the cohorts were combined. The impact of this on model precision and significance could be investigated by quota sampling across the range of BMI and NFG/IFG/T2D, at the cost of generalisability. High levels of education limits generalizability, but the presence of significant associations in this healthy, highly educated community-living sample indicates the importance of the association between blood glucose and BMI on brain volumes in ageing.

Acknowledgements:

The authors are grateful to Naftali Raz, Anthony Jorm, Chantal Réglade-Meslin, Jerome Maller, Patricia Jacomb, Karen Maxwell, and the PATH project interviewers.

Funding:

The study was supported by NHMRC of Australia Grants [973302,179805,157125,1002560,1063907 and 120100227]. Research was partly undertaken on the National Computational Infrastructure in Canberra, Australia, supported by the Australian Commonwealth Government.

References

1. Potvin O, Mouiha A, Dieumegarde L, Duchesne S, Initiative AsDN. Normative data for subcortical regional volumes over the lifetime of the adult human brain. *NeuroImage*. 2016;137:9-20.
2. Enzinger C, Fazekas F, Matthews P, Ropele S, Schmidt H, Smith S, et al. Risk factors for progression of brain atrophy in aging Six-year follow-up of normal subjects. *Neurology*. 2005;64(10):1704-11.
3. Organization WH. Global report on diabetes: World Health Organization; 2016.
4. van Bloemendaal L, Ijzerman RG, Jennifer S, Barkhof F, Diamant M, Veltman DJ, et al. Alterations in white matter volume and integrity in obesity and type 2 diabetes. *Metab Brain Dis*. 2016;31(3):621-9.

5. Walsh EI, Shaw M, Sachdev P, Anstey KJ, Cherbuin N. Brain atrophy in ageing: Estimating effects of blood glucose levels vs. other type 2 diabetes effects. *Diabetes Metab.* 2017;In press.
6. Mortby ME, Janke AL, Anstey KJ, Sachdev PS, Cherbuin N. High "normal" blood glucose is associated with decreased brain volume and cognitive performance in the 60s: the PATH through life study. *PloS one.* 2013;8(9):e73697.
7. Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. *Neurology.* 2012;79(10):1019-26.
8. Heikkilä O, Lundbom N, Timonen M, Groop P-H, Heikkinen S, Mäkimattila S. Evidence for abnormal glucose uptake or metabolism in thalamus during acute hyperglycaemia in type 1 diabetes—a 1H MRS study. *Metab Brain Dis.* 2010;25(2):227-34.
9. Tabatabaei-Jafari H, Shaw ME, Cherbuin N. Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.* 2015;1(4):487-504.
10. Gilbertson MW, Shenton ME, Ciszewski A, Kasai K, Lasko NB, Orr SP, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. *Nat Neurosci.* 2002;5(11):1242.
11. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. *The Lancet Neurology.* 2012;11(11):1006-12.
12. Anstey KJ, Christensen H, Butterworth P, Eastal S, Mackinnon A, Jacomb T, et al. Cohort Profile: The PATH through life project. *International journal of epidemiology.* 2011:dyr025.
13. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. *Medicine and science in sports and exercise.* 2000;32(9; SUPP/1):S498-S504.

14. Shaw ME, Sachdev PS, Anstey KJ, Cherbuin N. Age-related cortical thinning in cognitively healthy individuals in their 60s: The PATH Through Life study. *Neurobiol Aging*. 2016;39:202-9.
15. Fischl B. FreeSurfer. *Neuroimage*. 2012;62(2):774-81.
16. Mueller K, Anwender A, Möller HE, Horstmann A, Lepsien J, Busse F, et al. Sex-dependent influences of obesity on cerebral white matter investigated by diffusion-tensor imaging. *PloS one*. 2011;6(4):e18544.
17. den Heijer T, Vermeer S, Van Dijk E, Prins N, Koudstaal PJ, Hofman A, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. *Diabetologia*. 2003;46(12):1604-10.
18. Walsh E, Shaw M, Sachdev P, Anstey K, Cherbuin N. Brain atrophy in ageing: Estimating effects of blood glucose levels vs. other type 2 diabetes effects. *Diabetes & metabolism*. 2018;44(1):80-3.
19. Organization WH. Global status report on noncommunicable diseases 2014: Geneva: World Health Organization; 2014.

Table 1. Participant characteristics

	All	NFG	IFG	T2D
Age	64.66 (9.79)	63.66 (9.63)	65.79 (9.98)	69.99 (8.74)
BMI	27.22 (4.83)	26.48 (4.55)	28.44 (4.81)	30.34 (5.2)
Glucose (mmol/L)	5.45 (1.21)	5.05 (0.45)	5.92 (0.68)	7.53 (2.68)
Total Brain Volume (mm ³)	1119.57 (112.36)	1124.94 (112.72)	1123.92 (105.95)	1069.36 (112.48)
Grey Matter Volume (mm ³)	587.9	590.22	589.96	565.88

	(55.14)	(55.2)	(52.06)	(57.16)
Thalamus Volume (mm ³)	15.54 (1.61)	15.62 (1.62)	15.61 (1.58)	14.85 (1.46)
White Matter Volume (mm ³)	502.42 (60.85)	505.14 (61.37)	504.35 (57.26)	477.64 (59.74)
Corpus Callosum Volume (mm ³)	2.86 (0.54)	2.91 (0.55)	2.81 (0.44)	2.55 (0.49)
METs	48.88 (46.67)	47.68 (46.55)	57.23 (50.72)	40.91 (36.33)
Gender:Male	251 (50.81)%	159 (45.04)%	64 (67.37)%	28 (60.87)%
Gender:Female	243 (49.19)%	194 (54.96)%	31 (32.63)%	18 (39.13)%
Smoking:No	273 (56.76)%	195 (56.69)%	51 (55.43)%	27 (60)%
Smoking:Yes	208 (43.24)%	149 (43.31)%	41 (44.57)%	18 (40)%

Note. Due to missingness, some counts may not sum to the total sample size.

Table 2. Brain volume quartiles

	τ 0.25	τ 0.5	τ 0.75	
Total brain volume (ml)	[773, 1040]	(1040, 1120]	(1120, 1190]	(1190, 1500]
Grey matter volume (ml)	[423, 547]	(547, 586]	(586, 625]	(625, 754]
Thalamus volume (ml)	[12, 15.1]	(15.1, 16.3]	(16.3, 17.4]	(17.4, 21.7]
White matter volume (ml)	[330, 461]	(461, 500]	(500, 539]	(539, 744]
Corpus callosum volume (ml)	[0.98, 2.49]	(2.49, 2.83]	(2.83, 3.23]	(3.23, 4.8]

Figure 1. Model slopes and significance

Note. points are regression slopes, with 95% bootstrap confidence intervals (2500 replicates).

Triangle indicates significance ($\alpha < 0.05$). Tau is the boundary between quartiles, [0-25%], (25-50%], (50-75%], (75-100%], corresponding to the slope at the 25th, 50th, and 75th of each percentile. All models control for intracranial volume, sex, age, cohort, years of education, hypertension, and diabetes status.

Author Manuscript

